recomLine Parvovirus B19
against human parvovirus B19
Mikrogen recomLine Parvovirus B19 tests allow an indication of the time of infection due to the reactivity patterns of the recombinant antigens and the possibility to detect avidity determination of the IgG antibodies.
The determination of antibodies against the NS-1 antigen can be helpful in clarifying persistent parvovirus B19 infections. By using VP-2 particles, a presentation of conformational epitopes to the otherwise presented linear epitopes is achieved.
Products
Advantages
- Separate detection of IgG and IgM antibodies - Antibody class control on the test strip
- Band pattern and avidity determination allow conclusions on infection status
- Parvovirus B19 infections during the last 4 weeks can be reliably excluded
- Excellent diagnostic quality due to internal controls and the use of VP2 particles
- Easy and clear interpretation due to easy-to-read banding
- Partial and full automation, software-based evaluation (recomScan) and integration with laboratory information system possible
- Highest sensitivity and specificity due to use of recombinant antigens:
| Antigen | Abbreviation | Size [kDA] |
| Main capsid antigen (conformational epitopes) | VP-2p | 65 |
| N-terminal half of the structural proteins VP-1 and VP-2 | VP-N | 60 |
| VP-1 specific segment (differentiation from VP-2) | VP-1S | 31 |
| Main capsid antigen (linear epitopes) | VP-2r | 56 |
| C-terminal half of the structural proteins VP-1 and VP-2 | VP-C | 42 |
| Non-structural protein NS-1 | NS-1 | 75 |
Safe and reliable
Validity check by integrated, strip-specific cutoff and antibody class controls
Flexible and compatible
Combination of all Mikrogen line immunoassays possible - uniform processing and interchangeable reagents
High Standard
CE mark: The recomLine Parovirus B19 test meets the high standard of the EC Directive 98/79/EC for in vitro diagnostic medical devices.